This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quintiles Named Preferred Provider In Phase I Market Report

Quintiles is the preferred Phase I service provider and most frequently cited as the leading provider for complex studies, according to 119 pharmaceutical and biotechnology professionals surveyed in Industry Standard Research’s (ISR) 2013 Phase I Study Trends and Market Outlook Report. This announcement comes on the heels of Quintiles’ recognition as the industry leader and highest in service quality in Phase II/III clinical research in a separate ISR report released in May.

“The early clinical development landscape continues to increase in complexity as candidate drug molecules and their biological targets become more complex and Phase I studies move into patient populations,” said Oren Cohen, M.D., Senior Vice President of Early Clinical Development at Quintiles. “We are delighted to be recognized as the industry’s preferred provider because it reflects our ability to deliver complex studies in an increasing complex environment, working with our customers to develop a pathway that informs go/no-go decisions with a high degree of confidence. Our scientific expertise and integrated offerings help customers increase their probability of making good development decisions.”

Survey respondents with responsibility and decision-making authority for Phase I study conduct and outsourcing activities selected Quintiles as the preferred provider among all Clinical Research Organization (CROs). They also ranked Quintiles as the most frequently cited service provider that biopharmaceutical companies turn to for complex studies, with therapeutic expertise, scientific knowledge, access to patient populations, patient/volunteer recruitment strategy, prior positive experience and overall value among the most important attributes for selecting a provider for complex studies.

More information about the ISR report is available at http://www.isrreports.com/product/2013-phase-i-study-trends-and-market-outlook/.

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 27,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-50 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs